pirbuterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
bronchodilators, phenethylamine derivatives	2199	38677-81-5

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

pirbuterol
(+/-)-Pirbuterol
pirbuterol acetate
pirbuterol hydrochloride
pirbuterol HCl

Molecular weight: 240.30
Formula: C12H20N2O3
CLOGP: -0.03
LIPINSKI: 0
HAC: 5
HDO: 4
TPSA: 85.61
ALOGS: -1.59
ROTB: 5

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.20	mg	Inhal.aerosol
30	mg	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.14 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1986	FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R03AC08	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Selective beta-2-adrenoreceptor agonists
ATC	R03CC07	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Selective beta-2-adrenoreceptor agonists
FDA MoA	N0000009922	Adrenergic beta2-Agonists
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058666	Adrenergic beta-2 Receptor Agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D020011	Protective Agents
MeSH PA	D019141	Respiratory System Agents
FDA EPC	N0000175779	beta2-Adrenergic Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bronchiectasis	indication	12295008	DOID:9563
Disorder of lung	indication	19829001	DOID:850
Bronchitis	indication	32398004	DOID:6132
Pulmonary emphysema	indication	87433001
Asthma	indication	195967001	DOID:2841
Asthma management	indication	406162001
Acute exacerbation of asthma	indication	708038006
Bronchospasm Prevention	indication
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypokalemia	contraindication	43339004
Conduction disorder of the heart	contraindication	44808001
Diabetes mellitus	contraindication	73211009	DOID:9351
Chronic myocardial ischemia	contraindication	413844008	DOID:3393

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.36	acidic
pKa2	13.79	acidic
pKa3	9.38	Basic
pKa4	2.77	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST				WOMBAT-PK	CHEMBL

External reference:

ID	Source
4019898	VUID
N0000147983	NUI
D00686	KEGG_DRUG
65652-44-0	SECONDARY_CAS_RN
4019495	VANDF
4019898	VANDF
C0071129	UMLSCUI
CHEBI:8245	CHEBI
CHEMBL1094966	ChEMBL_ID
DB01291	DRUGBANK_ID
CHEMBL1200444	ChEMBL_ID
4845	PUBCHEM_CID
C009118	MESH_SUPPLEMENTAL_RECORD_UI
7272	IUPHAR_LIGAND_ID
3477	INN_ID
38029-10-6	SECONDARY_CAS_RN
OG645J8RVW	UNII
221142	RXNORM
5307	MMSL
d00755	MMSL
001817	NDDF
001818	NDDF
001819	NDDF
108611006	SNOMEDCT_US
108612004	SNOMEDCT_US
372516006	SNOMEDCT_US
CHEMBL3989646	ChEMBL_ID
CHEMBL1997417	ChEMBL_ID

Pharmaceutical products:

None